188814-36-0 Usage
General Description
3-N-FMOC-3-(4-fluorophenyl)propionic acid is a chemical compound that belongs to the class of fluorine-substituted aromatic compounds. It is commonly used in the pharmaceutical industry as a building block for the synthesis of various molecules, particularly in the development of potential drug candidates. 3-N-FMOC-3-(4-FLUOROPHENYL)PROPIONIC ACID contains a 3-N-FMOC protecting group, which is commonly used in peptide synthesis to protect the N-terminal amine group of amino acids. The presence of the 4-fluorophenyl moiety in the structure also confers specific chemical and biological properties that make this compound attractive for medicinal chemistry applications. Overall, 3-N-FMOC-3-(4-fluorophenyl)propionic acid is a versatile chemical building block with important applications in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 188814-36-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,8,8,1 and 4 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 188814-36:
(8*1)+(7*8)+(6*8)+(5*8)+(4*1)+(3*4)+(2*3)+(1*6)=180
180 % 10 = 0
So 188814-36-0 is a valid CAS Registry Number.
InChI:InChI=1/C24H20FNO4/c25-16-11-9-15(10-12-16)22(13-23(27)28)26-24(29)30-14-21-19-7-3-1-5-17(19)18-6-2-4-8-20(18)21/h1-12,21-22H,13-14H2,(H,26,29)(H,27,28)
188814-36-0Relevant articles and documents
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.
